Supplementary Table 1. Primer Sequences Used in RT-PCR Analysis

Supplementary Table 1. Primer sequences used in RT-PCR analysis

L32 Forward TGAAGCAGGCATCTGAGGG Reverse CGAAGGTGGAAGAG TGGGAG LIFR Forward CTCTCAGGCCAGAGTTGAGC Reverse GCTGTTCAGTCAGCCCTCTC CCR2 Forward TGTCTTCCCTGAATTGAGCC Reverse AAACGCATTAGTGGACAGGG IL12R Forward CGCAATACGTCGTGCGCTGC Reverse CACTCTGACTCCCACGCGCC CSF1R Forward GCTGGTGCGGATTCGAGGGG Reverse TTCGGCGTTAGTGGCCGAGC TGFbR1 Forward ACGCGCTGACATCTATGCAA Reverse CGTCGAGCAATTTCCCAGAA TGFbR2 Forward GCGCATCGCCAGCACGATCC Reverse TGGGCTTCCATTTCCACATCCGA CXCR1 Forward TCCTCCTGCCGCTGCTCACT Reverse CATGCGCAGTGTGAGCCCGT CXCR2 Forward CCTCGTGCCGCTGCTCATCA Reverse GGTGCGCAGTGTGAACCCGT CXCR3 Forward GGTCGCACTGCTCTGCGTGT Reverse GGGGCAGCAGGAAACCAGCC CXCR4 Forward GAGGCGTTTGGTGCTCCGGT Reverse TCGGTTCCATGGCAACACTCGC VEGFR1 (Flt1) Forward CGCGTGAAGAGTGGGTCCT Reverse CACATGCACGGAGGTGTTG VEGFR2 (Flk1) Forward AGCCCAGACTGTGTCCCGCA Reverse GGTGTCCGCGGAATCGGGTC VEGFR3 (Flt4) Forward GCCCGAGGACGAGGGTGACT Reverse CCTGGCTGCGCCTATCCTGC human Flt1 Forward GCACGTCAGCGAAGGCAAGC Reverse CCAGCTCAGCGTGGTCGTAGG Supplementary Table 2. List of putative miR-200 target genes amplified in human cancers

amplified in cancers (Tumorscape)a Gene Symbol Title various cancers NSCLC PCT Errfi1 ERBB receptor feedback inhibitor 1 - yes 0.94 D11Bwg0517e DNA segment, Chr 11, Brigham & Women's Genetics 0517 expressed - yes 0.91 Pvrl4 poliovirus receptor-related 4 yes - 0.91 Mecp2 methyl CpG binding protein 2 yes yes 0.9 Jun Jun oncogene yes - 0.88 Prdm16 PR domain containing 16 - yes 0.88 Flt1 FMS-like tyrosine kinase 1 yes - 0.87 Efnb2 ephrin B2 - yes 0.86 5830417C01Rik RIKEN cDNA 5830417C01 gene yes yes 0.86 Dnajc5 DnaJ (Hsp40) homolog, subfamily C, member 5 yes yes 0.84 Kras v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog yes yes 0.84 Wnk1 WNK lysine deficient protein kinase 1 - yes 0.84 Nptx1 neuronal pentraxin 1 - yes 0.81 Npc1 Niemann Pick type C1 yes yes 0.78 Ppp1r9a protein phosphatase 1, regulatory (inhibitor) subunit 9A yes yes 0.78 Myt1 myelin transcription factor 1 yes yes 0.72 Nup153 nucleoporin 153 yes - 0.72 Lhfp lipoma HMGIC fusion partner yes - 0.7 Gigyf1 GRB10 interacting GYF protein 1 - yes 0.69 Vegfa vascular endothelial growth factor A yes yes 0.66 Stard13 StAR-related lipid transfer (START) domain containing 13 yes - 0.64 Med13 mediator complex subunit 13 - yes 0.63 Dek DEK oncogene (DNA binding) yes - 0.61 Atxn1 ataxin 1 yes - 0.6 Frem2 Fras1 related extracellular matrix protein 2 yes - 0.59 Pds5b PDS5, regulator of cohesion maintenance, homolog B (S. cerevisiae) yes - 0.58 Foxf2 forkhead box F2 yes - 0.56 Tera teratocarcinoma expressed, serine rich yes yes 0.56 Reln reelin - yes 0.54 Sox2 SRY-box containing gene 2 yes - 0.52 Pan3 PAN3 polyA specific ribonuclease subunit homolog (S. cerevisiae) yes - 0.51 Mapk7 mitogen-activated protein kinase 7 yes - 0.5 Lats2 large tumor suppressor 2 yes - 0.5 Eif5a2 eukaryotic translation initiation factor 5A2 yes yes 0.5 Arid4b AT rich interactive domain 4B (Rbp1 like) - yes 0.49 Eif2b5 eukaryotic translation initiation factor 2B, subunit 5 epsilon yes - 0.49 Etv5 ets variant gene 5 yes - 0.45 Tardbp TAR DNA binding protein - yes 0.44 Atp11b ATPase, class VI, type 11B yes - 0.43 Fndc3b fibronectin type III domain containing 3B yes - 0.41 Ipo8 importin 8 - yes 0.41 Tbl1xr1 transducin (beta)-like 1X-linked receptor 1 yes - 0.39 Trio triple functional domain (PTPRF interacting) - yes 0.33 Stk10 serine/threonine kinase 10 - yes 0.31 MtMet mettt proto-oncogene yes yes 0230.23 A530082C11Rik RIKEN cDNA A530082C11 gene yes - 0.23 Ubxd7 UBX domain containing 7 yes - 0.14 Mycn v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) yes - <0.1 Ulk2 Unc-51 like kinase 2 (C. elegans) yes - <0.1 Arhgef7 Rho guanine nucleotide exchange factor (GEF7) - yes <0.1 aPutative miR-200 target genes are indicated as either amplified (yes) or not amplified (-) in non-small cell lung cancer (NSCLC) and other cancer types (various cancers).